Skip to main content

Rosai-Dorfman Disease clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

    open to all eligible people

    This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

    at UCSF

Our lead scientists for Rosai-Dorfman Disease research studies include .

Last updated: